S&P 500 Industrials Sector SEC Filings — March 30, 2026

30-03-2026

Ingevity Corporation, along with Ingevity Holdings SRL and Ingevity UK Ltd, entered into a Second Amendment and Restatement Agreement dated March 26, 2026, amending their existing credit agreement to establish new Revolving Commitments totaling $750 million, with proceeds used to repay all outstanding revolving loans under the prior facility. The transaction involves JPMorgan Chase Bank, N.A. as Administrative Agent and other lenders, with effectiveness subject to standard conditions including legal opinions, solvency certificates, and repayment of prior obligations. No comparative financial metrics or performance declines are disclosed in the filing.

• ·Existing Credit Agreement originally dated June 23, 2022
• ·Amendment Arrangers: JPMorgan Chase Bank, N.A., BofA Securities, Inc., Citizens Bank, N.A., PNC Bank, National Association, TD Securities (USA) LLC
• ·Legal opinions required from Wachtell, Lipton, Rosen & Katz, McGuireWoods LLP, Loyens & Loeff CVBA, NautaDutilh BV/SRL, Cahill Gordon & Reindel (UK) LLP
• ·Engagement Letter dated February 19, 2026

30-03-2026

Baker Hughes Co's DEF 14A Proxy Statement filed March 30, 2026, discloses 5% shareholders including The Vanguard Group (121,897,643 shares, 12.29%), JPMorgan Chase & Co. (86,781,218 shares, 8.75%), BlackRock Inc. (84,558,359 shares, 8.53%), and State Street Corporation (65,170,011 shares, 6.57%), with 991,757,347 Class A Common Stock shares outstanding as of March 23, 2026. Current directors, nominees, and executive officers as a group beneficially own 1,839,049 shares (less than 1%), including vested DSUs for directors ranging from 0 to 53,880.774 as of December 31, 2025. Related party transactions include $250,000 compensation in 2025 to an immediate family member of CEO Lorenzo Simonelli and $150,000 annual compensation approved for the son of director Cynthia B. Carroll effective April 2026.

• ·Company's Insider Trading Policy prohibits directors and executive officers from derivative transactions in Company stock and pledging shares as collateral.
• ·No personal loans or extensions of credit to directors or executive officers.
• ·Governance & Corporate Responsibility Committee reviews related person transactions per Item 404 of Regulation S-K.

30-03-2026

CBAK Energy reported explosive Q4 2025 consolidated net revenues of $58.80 million, up 131.8% YoY from $25.37 million, fueled by 524.2% growth in Light Electric Vehicles (LEV) to $12.92 million and 944.1% surge in Hitrans battery raw materials to $27.98 million; however, Electric Vehicles declined 91.1% to $0.06 million and Residential Energy Supply & UPS fell 10.6% to $17.84 million. Full year 2025 revenues grew 11% to $195.19 million from $176.61 million, with LEV up 252% to $36.36 million and Hitrans up 123% to $89.21 million, but Battery Business total dropped 22% due to a 45% decline in Residential Energy Supply & UPS to $68.82 million, resulting in gross margin compression to 9.4% from 23.7% and a net loss of $9.38 million versus $11.79 million net income in 2024.

• ·Q4 2025 gross profit $4.28M (margin 7.3%) vs $3.31M (13.1%) in Q4 2024.
• ·FY 2025 cost of revenues $176.77M including $6.61M inventory write-downs.
• ·Q4 2025 operating loss $8.01M vs $6.59M in Q4 2024; FY 2025 operating loss $18.44M vs $8.79M income in FY 2024.
• ·Q4 R&D expenses $5.30M (up from $3.80M); FY R&D $15.80M (up 21%).
• ·Cash increased to $75.68M as of Dec 31, 2025 from $60.79M.

30-03-2026

Boeing Co (BA-PA) filed a DEFA14A Definitive Additional Proxy Statement on March 30, 2026. The provided content consists solely of standard boilerplate language referencing SEC filings such as Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, along with a forward-looking statements disclaimer. No specific financial data, proposals, or material updates are detailed in the excerpt.

30-03-2026

AEON Biopharma reported full year 2025 financial results showing a net loss of $39,222 thousand versus net income of $42,005 thousand in 2024, driven by operating losses of $12,803 thousand and negative fair value changes, though R&D expenses declined 71% to $4,094 thousand and cash increased to $3,006 thousand. Positive developments include positive initial comparative analytical results for ABP-450 biosimilar (100% amino-acid sequence match to BOTOX®), constructive FDA BPD Type 2a feedback, $6 million PIPE financing with $4.2 million additional proceeds in January 2026, and over 90% reduction in outstanding debt. The company strengthened leadership with John Bencich as CFO and anticipates completing most analytical comparability work in 2026.

• ·LC/MS analysis demonstrated 93–99% sequence coverage across all five proteins in the 900 kDa botulinum toxin type A complex.
• ·Cash and cash equivalents expected sufficient to fund operations into Q3 2026 including $4.2M PIPE proceeds.
• ·Abstract accepted for poster presentation at 2026 AAN Annual Meeting (April 18-22, 2026) on primary structure comparability of ABP-450.
• ·Convertible notes at $34,600 thousand (including $34,600 thousand related party) as of Dec 31, 2025 vs $11,689 thousand in 2024.
• ·Stockholders' deficit increased to $(55,027) thousand from $(28,569) thousand.

30-03-2026

S&T Bancorp's 2026 Proxy Statement discloses 2025 non-employee director compensation totaling $70,000 to $165,833 per director, primarily from $70,000 annual cash retainers and $50,000 restricted stock units (1,290 units at $38.76/share), with prorated awards for new director Stephanie N. Doliveira ($40,833 cash + $29,167 stock) and forfeited stock for resigned Christine J. Toretti ($160,000 cash only). Ernst & Young audit fees increased 0.7% YoY to $1,313,737 while tax fees declined 12.3% to $195,660, with audit-related fees flat at $31,973. The Board revised stock ownership guidelines to 4x the annual cash retainer effective post-January 28, 2026.

• ·No political contributions or spending in fiscal 2025.
• ·Revised stock ownership guidelines require directors to own 4x annual cash retainer ($280,000) by later of five years from January 28, 2026 or five years from initial appointment.
• ·All directors satisfied prior stock ownership guidelines ($100,000/$250,000 thresholds) as of January 28, 2026.
• ·Aon plc deemed independent by Compensation Committee for 2025 consulting services.
• ·Ernst & Young ratified as independent auditors for fiscal 2026.

30-03-2026

Endeavour Silver Corp (EXK) filed its 40-F Annual Report for the year ended December 31, 2025, including audited consolidated financial statements by KPMG LLP for 2025 and 2024, MD&A, and Annual Information Form. Audit fees increased 64.8% YoY to $1,910,726 from $1,159,465, while tax fees and all other fees remained flat at $0 for both years.

• ·Financial statements cover years ended December 31, 2025 and 2024.
• ·Auditor: KPMG LLP (Vancouver, BC, Canada; Auditor Firm ID: 85).
• ·Filing includes Inline XBRL documents (Exhibits 101.INS through 101.PRE).

30-03-2026

Reviva Pharmaceuticals reported a reduced net loss of $19.9 million for FY2025 ($5.48 per share) compared to $29.9 million ($17.73 per share) in FY2024, driven by lower R&D expenses ($11.7M vs. $22.9M), with cash at $14.4M at year-end and ~$23M post-March 2026 offering to fund into Q1-2027. However, G&A expenses rose slightly to $8.5M, and FDA feedback requires a second Phase 3 RECOVER-2 trial in mid-2026 before NDA for brilaroxazine in schizophrenia, despite positive 1-year OLE data showing sustained efficacy (PANSS total -18.1) and favorable safety. The company raised $29M gross via three equity offerings in 2025-2026.

• ·1-year OLE: PANSS total score improvement -18.1; positive symptoms -5.0; negative symptoms -4.4; <1% relapse.
• ·Weight gain ~1.5 kg over 52 weeks; no clinically meaningful movement disorders; favorable lipids, glucose, prolactin normalization.
• ·NDA-enabling carcinogenicity studies completed; cGMP manufacturing of drug substance and product batches done.
• ·Three new U.S. provisional patents filed; EP3749324 granted for pulmonary fibrosis.

30-03-2026

General Enterprise Ventures, Inc. reported revenue of $2,381,407 for the year ended December 31, 2025, marking a 195% increase from $808,372 in 2024. However, operating expenses surged 209% to $18,877,398, other expenses skyrocketed 1,190% to $20,341,652, and the net loss widened dramatically by 435% to $36,837,643 from $6,881,722. The company highlighted ongoing risks including high leverage, stock volatility, dilution from share issuances, and challenges in achieving profitability.

• ·Recent sales of unregistered securities included 220,000 shares for IP acquisition valued at $1,775,400 from Breakthrough Chemistry, Inc.
• ·346,127 shares issued via cashless conversion of 359,375 warrants.
• ·500,000 shares issued upon conversion of 150,000 shares of Series C Convertible Preferred Stock.
• ·475,862 shares issued for conversion of $1,071,821 in debt and accrued interest.
• ·55,333 shares issued for services valued at $443,377.

30-03-2026

ConocoPhillips filed DEFA14A additional proxy materials for its 2026 Annual Meeting of Stockholders on May 12, 2026, at 9:00 a.m. Central Time via virtual webcast. Key proposals include election of 13 director nominees, ratification of Ernst & Young LLP as independent auditors for 2026, and advisory approval of executive compensation (Board recommends FOR all), alongside a stockholder proposal for an independent board chairman (Board recommends AGAINST). The record date is March 18, 2026, with voting available online via ProxyVote.com until deadlines varying by plan (e.g., May 11, 2026).

• ·Record date for shareholders: March 18, 2026
• ·Virtual meeting URL: www.virtualshareholdermeeting.com/COP2026
• ·Proxy materials available online or by request before April 28, 2026
• ·Board discretion on other matters at the meeting

30-03-2026

Osisko Development Corp. filed its Form 40-F Annual Report on March 30, 2026. The filing lists the company's Common Shares (no par value, trading symbol ODV) registered on the New York Stock Exchange and Warrants (exercisable for one Common Share at $10.70, trading symbol ODVWZ) on The Nasdaq Stock Market LLC.

30-03-2026

Artificial Intelligence Technology Solutions, Inc. (AITX) filed an 8-K on March 30, 2026, under Item 8.01 to furnish a press release titled 'AITX's RAD Reports Its Strongest ISC West Showing to Date,' attached as Exhibit 99.1. The filing notes that the information is furnished and not deemed filed for liability purposes. No financial metrics or period comparisons are disclosed.

• ·Filing Type: 8-K (Items 8.01, 9.01)
• ·Date of Report: March 30, 2026
• ·Registrant State: Nevada; CIK: 0001498148; EIN: 27-2343603
• ·Principal Address: 10800 Galaxie Avenue, Ferndale, Michigan 48220

30-03-2026

Amphenol Corporation entered into an Indenture dated March 30, 2026, with Amphenol Technologies Holding GmbH as issuer, Amphenol Corporation as guarantor, and U.S. Bank Trust Company, National Association as trustee, for the issuance of Notes. This agreement creates a direct financial obligation under Item 2.03. The filing incorporates an Officers’ Certificate establishing the Notes and lists various exhibits including legal opinions.

• ·Exhibits include: 4.1 (Indenture), 4.2 (Officers’ Certificate), 4.3 (Form of Global Note), 5.1 (Opinion of Latham & Watkins LLP, New York), 5.2 (Opinion of Latham & Watkins LLP, Frankfurt), 23.1 and 23.2 (Consents), 104 (XBRL Cover Page)
• ·Incorporated by reference into Registration Statement No. 333-293923

30-03-2026

Cottonwood Communities, Inc. (CROP) reported NAV of $1,013,012 as of December 31, 2025, reflecting a decline in NAV per share to $11.3574 from $12.0083 at year-end 2024 (-5.4% YoY), though a valuation guideline change added approximately $19.42 million ($0.32 per share). Total revenues fell 2.9% YoY to $153,934 from $158,483, with rental revenues down 4.8% to $138,787, but Core FFO rose sharply 266% to $15,932 from $4,348, and net loss attributable to controlling interests improved to $(4,844) from $(10,956). The company repurchased 1,374,067 shares in Q4 2025 at an average price of about $11.29 per share.

• ·FFO per common share and unit - diluted: $(0.23) in 2025 vs $(0.01) in 2024.
• ·Core FFO per common share and unit - diluted: $0.22 in 2025 (up from $0.07).
• ·Stockholders’ equity: 282,807 as of Dec 31, 2025.
• ·Weighted-average diluted common shares and units: 71,259,649 in 2025 (up from 66,472,501).

30-03-2026

SmartStop Self Storage REIT, Inc. filed an 8-K on March 30, 2026, under Items 7.01 and 9.01, furnishing investor presentation materials as Exhibit 99.1 for use in investor communications pursuant to Regulation FD. The materials are deemed furnished and not filed, avoiding liabilities under Section 18 of the Exchange Act. The report was signed by James R. Barry, Chief Financial Officer and Treasurer.

• ·Securities: Common Stock, $0.001 par value, trading symbol SMA on New York Stock Exchange
• ·Principal executive offices: 10 Terrace Road, Ladera Ranch, California 92694
• ·Telephone: (866) 418-5144

30-03-2026

Electra Battery Materials Corp's 20-F Annual Report for the year ended December 31, 2025, shows significant improvements in liquidity risk, with short-term liabilities (<1 year) decreasing 44% to $6,623 from $11,797 in 2024, primarily due to the absence of convertible notes payable. Medium-term (1-2 years) liabilities dropped over 99% to $79 from $9,755, and long-term (>2 years) liabilities declined 59% to $44,045 from $107,633. Foreign currency net USD exposure also improved markedly, reducing to -$16,128 CAD from -$65,132 CAD, driven by higher cash balances and lower debt.

• ·2025 short-term liabilities include accounts payable and accrued liabilities of $5,817 and deferred government grant of $642.
• ·Convertible notes payable of $8,057 (<1 year), $8,012 (1-2 years), and $99,071 (>2 years) present in 2024 liquidity table but absent in 2025.
• ·2025 USD-denominated cash and cash equivalents rose to $25,019 (CAD) from $3,391 (CAD) in 2024.

30-03-2026

CISO Global serves more than 437 clients across diverse sectors, with penetration of only approximately 20% for multiple services, positioning the company for revenue growth through cross-selling and upselling. However, it incurred significant operating losses during the years ended December 31, 2025 and 2024, has limited cash flow, and faces substantial doubt about its ability to continue as a going concern, with the auditor's opinion including an explanatory paragraph on this matter. The filing highlights strategic strengths like proprietary software and partnerships alongside extensive risk factors including talent shortages, long sales cycles, and competitive pressures.

• ·Dependence on a significant customer for a material portion of revenue and accounts receivable.
• ·Expectation not to pay cash dividends in the foreseeable future.
• ·Industry shortage of qualified compliance and cybersecurity professionals.
• ·Long and unpredictable sales cycles.
• ·Auditor’s opinion on financial statements for year ended December 31, 2025, includes going concern explanatory paragraph.

30-03-2026

Hyperion DeFi, Inc. reported revenue of $813,455 for FY 2025, up significantly from $57,336 in FY 2024, with gross profit turning positive at $510,165 from a $3,869,892 loss; net loss narrowed to $45,314,435 from $49,818,433. However, the company recorded massive impairments and unrealized losses on digital assets totaling over $36 million, alongside elevated SG&A expenses of $17,175,698 (up from $14,333,114), while R&D expenses dropped sharply to $1,910,430 from $14,462,722. Liquidity improved markedly with cash rising to $6,443,467 from $2,121,463 and working capital turning positive at $4,544,796 from a $13,279,008 deficit.

• ·Notes Payable (Gross) decreased to $8,339,366 as of Dec 31, 2025 from $10,740,402 as of Dec 31, 2024.
• ·Total Stockholders’ Equity turned positive at $41,060,507 as of Dec 31, 2025 from a deficit of $(13,095,952) as of Dec 31, 2024.
• ·Net Loss per Share improved to $(9.40) from $(59.81), with weighted average shares outstanding at 5,000,331 vs 832,997.

30-03-2026

GBank Financial Holdings Inc. reported net income of $20.9 million for the year ended December 31, 2025, up 12% from $18.6 million in 2024, with diluted EPS increasing to $1.44 from $1.39 and loan growth of $143.3 million or 18% YoY. However, profitability metrics declined with return on average assets falling to 1.70% from 1.85%, return on average equity dropping to 13.61% from 16.14%, and net interest margin compressing to 4.33% from 4.79%, while non-performing assets rose sharply to $37.4 million or 2.75% of total assets from $14.2 million or 1.26%. Noninterest income surged 56.2% to $25.3 million driven by net interchange fees up 477% and loan servicing up 81%, but noninterest expenses increased 24.4% to $45.1 million.

• ·Average earning assets increased to $1,171.8 million in 2025 from $963.9 million in 2024.
• ·Total interest-bearing deposits grew to $806.1 million average in 2025 from $622.6 million in 2024.
• ·Guaranteed loans totaled $229.7 million as of Dec 31, 2025, slightly down from $233.9 million as of Dec 31, 2024.
• ·Net interest income rose $4.5 million or 9.8% to $50.7 million in 2025.

30-03-2026

On March 30, 2026, Addentax Group Corp. completed the acquisition of 34,200,000 shares of common stock in Keemo Fashion Group Limited from Guang Wen Global Group Limited for approximately $5.5 million, satisfied through the transfer of a portion of an existing bond. Following the transaction, the Company holds approximately 62.18% of the voting rights on a fully diluted basis, making Keemo Fashion a controlled subsidiary. No negative financial impacts or performance declines are disclosed.

• ·Stock Purchase Agreement originally dated February 17, 2026, previously disclosed in 8-K filings on February 19, 2026 and 8-K/A on March 16, 2026
• ·Exhibit 104: Cover Page Interactive Data File (embedded within the Inline XBRL document)

30-03-2026

Emerson Radio Corp. held its annual shareholder meeting on March 24, 2026, for the fiscal year ended March 31, 2025, with 18,304,342 shares represented, equating to 87% of outstanding common stock as of the February 6, 2026 record date. All four director nominees—Christopher Ho, Michael Binney, Kareem E. Sethi, and Kin Yuen—were elected, each receiving over 94% of votes cast excluding broker non-votes. Proposal 2 to ratify Grassi & Co., CPAs, P.C. as independent auditors for the fiscal year ending March 31, 2026 passed overwhelmingly with 17,665,995 votes in favor out of 18,304,342 total shares represented.

• ·Director election votes: Christopher Ho (15,473,456 for, 901,180 withheld); Michael Binney (15,457,320 for, 917,316 withheld); Kareem E. Sethi (15,995,476 for, 379,160 withheld); Kin Yuen (15,991,060 for, 383,576 withheld).
• ·Auditor ratification: 0 broker non-votes.
• ·Proxy statement filed February 20, 2026; record date February 6, 2026.

30-03-2026

Phio Pharmaceuticals Corp. announced on March 30, 2026, that it has entered into a cGMP drug product manufacturing services agreement with a U.S. manufacturer for clinical supply production. The full press release is attached as Exhibit 99.1 and incorporated by reference. The filing was signed by Robert J. Bitterman, President & Chief Executive Officer.

30-03-2026

Connect Biopharma announced positive topline results from its Phase 1 study (CBP-201-105) of intravenous rademikibart (300 mg, 2-minute IV push) in asthma and COPD patients, showing rapid FEV1 improvements of ≥200 mL in many patients as early as 15 minutes post-dosing, with mean improvements of ~200-400 mL maintained through Day 29 versus placebo decline. The treatment was generally well-tolerated with no serious adverse events, no severe AEs, and no discontinuations. Ongoing Phase 2 Seabreeze STAT studies expect topline data in mid-2026.

• ·Mean baseline FEV1: 1.9 L (asthma), 1.55 L (COPD)
• ·Randomized 4:1 rademikibart:placebo
• ·Exclusive license to Simcere for rademikibart in Greater China with royalties up to low double-digits
• ·Conference call and webcast on March 30, 2026 at 8:00 a.m. ET

30-03-2026

Douglas G. Thompson resigned as CEO and Managing Director effective March 31, 2026, to pursue new opportunities, leading the Board to reduce its size from seven to six members. Garold Spindler, age 78 and current Executive Chair with extensive coal industry experience, was appointed Interim CEO effective April 1, 2026, under a new employment agreement with an annual base salary of $1,250,000. Additionally, Greg Pritchard was appointed Board Chair effective the same date.

• ·Mr. Thompson informed of resignation on February 22, 2026 (February 23 in Australia).
• ·Mr. Spindler previously served as CEO from August 2018 to May 2023.
• ·Employment agreement dated March 27, 2026; terminable with 30 days' notice; includes 1-year non-compete.
• ·No family relationships or related party transactions with Mr. Spindler.

30-03-2026

Terrestrial Energy reported a $28 million net loss for FY 2025, a $17 million increase from FY 2024, driven by higher R&D (+$5M), G&A (+$10M), and interest expenses (+$2M), with revenue falling to $0 from $248,357. The company made significant progress including Texas A&M selection for IMSR deployment at RELLIS campus, DOE OTA awards for TETRA and TEFLA pilots, NRC acceptance of IMSR design criteria, and completion of business combination with HCM II Acquisition Corp raising $292 million in gross proceeds, boosting cash and short-term investments to $298 million. Shares outstanding totaled 105.8 million as of December 31, 2025.

• ·Operating loss of $25.2M for FY 2025 vs $10.4M for FY 2024.
• ·Total operating expenses $25.2M for FY 2025 (+138% YoY).
• ·NRC accepted IMSR Principal Design Criteria including inherent reactor control mechanisms.
• ·Conference call held March 30, 2026 at 8:30 a.m. ET.

30-03-2026

COPT DEFENSE PROPERTIES (CDP) filed a DEFA14A on March 30, 2026, classified as Definitive Additional Materials under Schedule 14A of the Securities Exchange Act of 1934. The filing was submitted by the registrant with no fee required. No specific financial data, proposals, or performance metrics are detailed in the provided filing header.

• ·Amendment No. (blank in filing)
• ·Soliciting Material under §240.14a-12

30-03-2026

Benchmark 2025-V19 Mortgage Trust filed its Form 10-K annual report for the fiscal year ended December 31, 2025, on March 30, 2026, including assessments of compliance with servicing criteria and servicer compliance statements from entities like Midland Loan Services and Citibank, N.A. Explanatory notes highlight that key mortgage loans—Empire Mall (6.8% of initial pool), 9911 Belward (4.1%), 1700 Pavillion (3.4%), and Central Arts Plaza (1.2%)—are parts of loan combinations serviced under separate PSAs such as WFCM 2025-5C7 and Benchmark 2025-V18. No material legal proceedings, significant obligors, or external credit enhancements are reported, with most traditional financial sections omitted as is standard for such trusts.

• ·No mortgage loan in the pool constitutes a significant obligor per Item 1101(k)(2) of Regulation AB.
• ·No external credit enhancement, derivative instruments, or other support for certificates.
• ·No unresolved staff comments, legal proceedings material to security holders, or cybersecurity disclosures required.

30-03-2026

Tri-State Generation and Transmission Association, Inc. disclosed that Wheat Belt Public Power District provided a non-conditional two-year notice of intent to withdraw from membership effective April 1, 2028, pursuant to Rate Schedule No. 281, amid ongoing court proceedings in the Tenth Circuit and D.C. Circuit. Wheat Belt comprised 1.35% of Tri-State’s utility member revenue and 0.89% of operating revenue for the year ended December 31, 2025, representing a minor potential revenue impact if withdrawal proceeds. Tri-State issued a press statement on the matter but cannot predict if Wheat Belt will ultimately withdraw.

• ·Notice provided on March 27, 2026.
• ·Ongoing proceedings at U.S. Court of Appeals for the Tenth Circuit and D.C. Circuit regarding elements of Rate Schedule No. 281.
• ·Press statement attached as Exhibit 99.1.

30-03-2026

Genprex, Inc.'s 10-K filing highlights substantial operational risks, including the need for additional funding, recurring losses raising substantial doubt about going concern status, and no history of profitability or revenue from product sales. The company faces significant challenges in clinical development and commercialization of REQORSA® and GPX-002, with risks of trial failures, regulatory delays, side effects, competition, and lack of market acceptance. Additional concerns include limited operating history, potential NOL limitations, employee matters, healthcare reforms, international operations, acquisition risks, and high stock price volatility.

30-03-2026

Deep Isolation Nuclear, Inc. reported annual revenue of $6,136 thousand for the year ended December 31, 2025, down 13% YoY from $7,053 thousand in 2024, while gross profit rose modestly 3% to $3,502 thousand amid a 28% reduction in cost of services. Operating expenses doubled to $9,272 thousand, driven by SG&A expenses surging 111% to $8,753 thousand, leading to an operating loss widening to $5,770 thousand from $1,066 thousand and net loss to $5,336 thousand from $994 thousand. However, financing activities provided $29,198 thousand, increasing cash to $27,432 thousand from $2,149 thousand.

• ·Common shares outstanding increased to 57,542,113 at Dec 31, 2025 from 39,901,782 at Dec 31, 2024 due to private placement (11,012,387 shares), stock options exercise (4,404,814 shares), and reverse acquisition adjustments.
• ·Pro forma fully diluted ownership: Deep Isolation Stockholders 63.89%, Private Placement Investors 13.23%.
• ·Net cash used in operating activities increased to $3,931 thousand from $1,201 thousand.
• ·Accounts receivable decreased to $439 thousand from $999 thousand.

30-03-2026

Legence Corp. reported FY2025 revenue of $2,550,491 thousand, up 21.5% YoY from $2,098,602 thousand, with data centers & technology surging to $1,087,800 thousand (42.7% of total, +50.1% YoY) and life sciences & healthcare growing to $459,186 thousand (+34.1% YoY). However, mixed-use revenue declined 25.6% to $118,365 thousand, education grew modestly at 7% to $427,885 thousand, and income from operations fell 12.5% to $61,582 thousand due to 41.1% higher SG&A and elevated impairments, widening net loss attributable to Legence to $(59,780) thousand from $(28,555) thousand. Gross profit rose 24.4% to $535,925 thousand with a slight 0.5 percentage point margin expansion to 21.0%.

• ·Engineering & Consulting gross margin declined 1.2 pts to 32.9%; Installation & Maintenance improved 1.2 pts to 16.3%.
• ·Goodwill impairment rose 40.2% to $24,966 thousand; new long-lived asset impairment of $2,415 thousand.
• ·Interest expense increased 11.1% to $101,778 thousand.
• ·State & local government revenue up 14.0% to $106,589 thousand (4.2% mix); Other category down 7.4% to $350,666 thousand (13.7% mix).

30-03-2026

Hines Global Income Trust reported total revenues of $425,203 thousand, up 22% YoY from $348,907 thousand, driven by recent acquisitions and a $149,639 thousand gain on real estate sale, swinging to net income of $17,589 thousand from a $47,093 thousand loss in 2024; NAV reached $2,926,525 thousand ($9.82 per share). However, total expenses rose 30% YoY to $402,234 thousand, interest expense increased 22%, and same-store office revenues declined 5% YoY while retail remained flat.

• ·Sources of distributions: 32% from operating cash flows, 54% DRP, 14% other sources in 2025.
• ·Performance participation allocation of $24,795 thousand recognized in 2025 (none in 2024).
• ·Class I shares ITD return 6.48%; Class S (with sales load) ITD return 5.04%.
• ·Impairment losses of $3,060 thousand in 2025.

30-03-2026

For the year ended December 31, 2025, ImmuCell Corp reported product sales growth of 4% YoY to $27,644,174, driven by a 13% decline in costs of goods sold, resulting in gross profit surging 44% to $11,445,203 and net operating income turning positive at $1,649,305 from a prior loss. However, administrative expenses increased 44%, other expenses net rose 429% to $2,677,762, and a $2,667,100 impairment charge on property, plant, and equipment was recognized after pausing investment in Re-Tain® manufacturing to focus on First Defense®, contributing to a narrowed net loss of $1,040,027 (52% improvement) while total assets declined 6% to $42,532,447.

• ·Net cash provided by operating activities increased to $2,475,292 in 2025 from $357,903 in 2024.
• ·Net cash used for investing activities was $1,214,307 in 2025 vs $461,225 in 2024.
• ·Inventory increased to $9,267,369 as of Dec 31 2025 from $7,112,623.
• ·Property, plant and equipment net decreased to $21,074,694 as of Dec 31 2025 from $25,349,019.
• ·Critical audit matters include valuation of inventory and impairment of PPE related to Re-Tain® assets.
• ·Leased properties total approx. 29,700 sq ft (175A and 175B Industrial Way) for milling, filling, warehouse.

30-03-2026

Theravance Biopharma subsidiaries and Mylan entered into a Settlement Agreement with Mankind Pharma Ltd. and Lifestar Pharma LLC on March 27, 2026, resolving Hatch-Waxman patent litigation over Mankind's ANDA for a generic version of YUPELRI® (revefenacin) inhalation solution. The agreement grants Mankind a royalty-free, non-exclusive license to launch the generic in the U.S. on or after April 23, 2039, subject to exceptions and antitrust review by the DOJ and FTC. This settlement resolves all pending Hatch-Waxman litigation related to YUPELRI.

• ·Settlement covers United States Patent Nos. 11,484,531, 12,048,692, and 12,285,417.
• ·License is non-sublicensable and non-transferable.
• ·Settlement subject to review by the U.S. Department of Justice and Federal Trade Commission.

30-03-2026

Falcon’s Beyond reported Q4 2025 consolidated revenue of $6.6 million and full year 2025 revenue of $14.9 million, up $8.2 million YoY due to the new Falcon's Attractions segment, with Q4 net loss narrowing to $0.3 million from $11.9 million in Q4 2024 and Adjusted EBITDA turning positive at $0.2 million versus a $12.0 million loss prior year. However, FCG full year revenue fell $14.5 million to $38.7 million due to project timing, PDP posted a Q4 net loss with Falcon’s share of $0.1 million, and full year consolidated Adjusted EBITDA was a $17.3 million loss amid integration costs. Full year consolidated net income of $6.3 million was driven by PDP's $60.0 million gain on Tenerife sale, partially offset by impairments.

• ·FCG contracted pipeline of $41.6 million as of end 2025.
• ·Settlement with FAST includes forfeiture of 360,000 Class A shares and 375,000 Class A unvested earnout shares upon deferred payment.
• ·Achieved first stock price-based earnout trigger, releasing 15,000,000 of 40,000,000 earnout shares and units.
• ·Cash and cash equivalents increased to $1.9 million from $0.8 million YoY; total debt reduced to $15.6 million from $41.2 million.

30-03-2026

On March 25, 2026, QuoteLab, LLC and QL Holdings LLC, subsidiaries of MediaAlpha, Inc., entered into an Amendment and Restatement Agreement amending their existing Credit Agreement, establishing a new $150 million five-year senior secured term loan facility to refinance prior term loans and support general corporate purposes, and a new $60 million five-year senior secured revolving credit facility. The facilities are guaranteed by Holdings and secured by substantially all assets of Holdings and the Borrower, with maturity on March 25, 2031, and term loan amortization beginning June 30, 2026. No performance declines or flat metrics are reported in this financing update.

• ·Borrowings bear interest at Term SOFR, Daily Simple SOFR, or Alternate Base Rate plus applicable margins based on consolidated total net leverage ratio.
• ·Term loans require prepayments from non-ordinary course asset sales, casualty, and condemnation events, subject to exceptions.
• ·Credit Agreement includes customary affirmative, negative, and financial covenants and default provisions.

30-03-2026

Hecla Mining Company filed an 8-K/A on March 30, 2026, amending its March 25, 2026 original 8-K to include unaudited pro forma condensed consolidated financial information for the years ended December 31, 2025, 2024, and 2023, and as of December 31, 2025, pursuant to Item 9.01(b). The amendment relates to the completion of the sale of its wholly-owned subsidiary, Hecla Quebec Inc., to 17629346 Canada Inc., an affiliate of Orezone Gold Corporation, on March 25, 2026. No other changes were made to the original report.

• ·Transaction initially announced on January 26, 2026, and disclosed in 8-K filed January 28, 2026.
• ·Pro forma financials attached as Exhibit 99.2.

30-03-2026

Designer Brands Inc. reported FY2025 consolidated net sales of $2,892,671 thousand, down 3.9% YoY from $3,009,262 thousand, with Retail segment sales declining 3.4% (comparable sales -3.9%) and Brand Portfolio down 9.0% (comparable -21.9%). Operating profit improved 36.7% to $47,764 thousand from $34,933 thousand, driven by lower impairment charges (down 75.9%) and reduced operating expenses (down 2.1%), though Retail operating profit fell 15.2% while Brand Portfolio surged 238.2%; net loss attributable to DBI narrowed 20.6% to $8,374 thousand from $10,549 thousand.

• ·Filing date: March 30, 2026
• ·Net cash provided by operating activities increased to $109,860 thousand from $82,236 thousand
• ·Basic and diluted loss per share improved to $(0.17) from $(0.20)
• ·Impairment charges decreased 75.9% to $4,419 thousand from $18,336 thousand

30-03-2026

Genco Shipping & Trading Ltd filed a DEFA14A on March 30, 2026, regarding proxy solicitation for its 2026 Annual Meeting of Shareholders, urging shareholders to review the definitive proxy statement, WHITE proxy card, and related SEC filings. The filing identifies participants in the solicitation, including independent directors (Paramita Das, Kathleen C. Haines, Basil G. Mavroleon, Karin Y. Orsel, Arthur L. Regan) and executives (John C. Wobensmith, Peter Allen, Joseph Adamo, Jesper Christensen). It references prior 2025 proxy statement and multiple Form 4 ownership change filings by these individuals, available on SEC and company websites.

• ·References to 2025 Annual Meeting proxy filed April 9, 2025.
• ·Form 4 filings by directors and executives on dates including May 22, 2025; June 3, 2025; August 26, 2025; September 10, 2025; September 15, 2025; November 12, 2025; November 26, 2025; February 18, 2026; February 23, 2026; March 20, 2026.
• ·Investor contact: Peter Allen, (646) 443-8550.
• ·Media contact: Leon Berman, (212) 477-8438, lberman@igbir.com.
• ·Documents available at www.sec.gov and https://investors.gencoshipping.com/

30-03-2026

Lulus reported Q4 FY2025 net revenue of $63.0 million, down 5% YoY due to an 11% decrease in total orders placed, though partially offset by 6% higher AOV to $137 and gross profit up 11% to $27.9 million with 640 bps margin expansion to 44.3%. For full FY2025, net revenue fell 11% to $282.3 million with active customers down 11% to 2.3 million, but Adjusted EBITDA improved to -$1.2 million from -$9.7 million amid 200 bps gross margin gains to 43.2%. The company expects FY2026 Adjusted EBITDA to turn positive with improving net revenue growth trends versus -11% in 2025, though Q1 2026 revenue and EBITDA are projected lower sequentially.

• ·Q4 FY2025 AOV increased 6% to $137 from $129 YoY
• ·FY2025 AOV increased 2% to $140 from $137 YoY
• ·Q4 FY2025 Total Orders Placed decreased 11% YoY
• ·FY2025 Total Orders Placed decreased 15% YoY
• ·FY2026 capex outlook $2.0-2.5 million
• ·Q1 FY2026 net debt expected $7.5-8.0 million
• ·1-for-15 reverse stock split effective July 7, 2025

30-03-2026

Edible Garden AG Incorporated entered into exchange agreements with Streeterville Capital, LLC on March 19, 2026 (55 shares), March 24, 2026 (1,054 shares), and March 26, 2026 (75 shares) of Series B Preferred Stock, totaling 1,184 shares with an aggregate stated value of $1,184,000, for 670,199 shares of common stock. The transactions were unregistered under the Securities Act, relying on the Section 3(a)(9) exemption. No other financial metrics or performance comparisons were reported.

• ·Exchange Shares priced based on Nasdaq Minimum Price on the day immediately preceding each agreement date.
• ·Company incorporated in Delaware, Commission File Number 001-41371, IRS EIN 85-0558704.
• ·Emerging growth company status confirmed.

30-03-2026

On March 30, 2026, IGC Pharma, Inc. announced a strategic national media partnership with FMW Media Works LLC (New to The Street) to bolster its investor relations and corporate communications initiatives. The details are provided in the attached press release (Exhibit 99.1), which is furnished but not filed under securities regulations.

• ·Filing includes Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits with Exhibit 99.1 as the press release)

30-03-2026

On March 25, 2026, SunPower Inc. held a Special Meeting of Stockholders, approving all six proposals, including the Second Amendment to the 2023 Equity Incentive Plan increasing shares reserved for issuance to 44,573,109. Stockholders also approved share issuances related to prior acquisitions, an additional $22,225,000 of 7.00% Convertible Senior Notes due 2029, increasing the White Lion Purchase Agreement commitment from $30.0 million to $55.0 million, and the Yorkville Standby Equity Purchase Agreement, with strong support across proposals (over 66 million votes for each). However, opposition was notable on Proposal 3 (3.05 million against), Proposal 5 (1.25 million against), and Proposal 6 (8.44 million against).

• ·Proposal 1 approved issuance of shares in excess of 3,333,334 related to September 21, 2025 Membership Interest Purchase Agreement.
• ·Proposal 2 approved shares issuable upon conversion of additional $22,225,000 7.00% Notes.
• ·Proposal 3 approved post-closing consideration shares in excess of 16,620,910 related to November 21, 2025 Membership Interest Purchase Agreement.
• ·Proposal 4 approved increase of White Lion commitment from $30.0 million to $55.0 million.
• ·Proposal 5 approved shares under Yorkville Purchase Agreement potentially exceeding 20% of outstanding Common Stock as of January 27, 2026.

30-03-2026

Blue Ridge Bankshares, Inc. amended and restated its warrants effective March 28, 2026, with holders representing a majority of underlying shares approving the change; the amendment reduces the per share exercise price by the amount of certain cash distributions to common stockholders, applying to dividends after the effective date including the November 2025 dividend. On March 30, 2026, the Board declared a special cash dividend of $0.60 per share, payable on April 27, 2026 to shareholders of record as of April 13, 2026.

• ·Warrant amendment approved by Board of Directors and holders representing a majority of shares underlying outstanding Warrants.
• ·The foregoing description of the warrant amendment is qualified by reference to Exhibit 4.1 (Form of Amended and Restated Common Stock Warrant).